FDA approves a second Alzheimer's drug that can modestly slow disease

This image provided by Eli Lilly shows the company's new Alzheimer’s drug Kisunla. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only theThe delay seen with both drugs amounts to a matter of months — about seven months, in the case of Lilly’s drug.

The new drug's approval was expected after an outside panel of FDA advisors unanimously voted in favor of its benefits at a public meeting last month. That endorsement came despite several questions from FDA reviewers about how Lilly studied the drug, including allowing patients to discontinue treatment after their plaque reached very low levels.

More than 6 million Americans have Alzheimer’s. Only those with early or mild disease will be eligible for the new drug, and an even smaller subset are likely to undergo the multi-step process needed to get a prescription.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

High Confidence Alzheimer's Drug Donanemab Will Get FDA Panel NodAn FDA advisory committee will meet June 10 to offer its opinion on whether the agency should greenlight donanemab for Alzheimer's disease.
Source: Medscape - 🏆 386. / 55 Read more »

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug would only be the second Alzheimer’s drug clearly shown to slow cognitive decline due to Alzheimer’s.
Source: AP - 🏆 728. / 51 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia.
Source: KPRC2 - 🏆 80. / 68 Read more »